The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Naprosin     2-(6-methoxynaphthalen-2- yl)propanoic acid

Synonyms: Floginax, Laraflex, Nycopren, Pranoxen, Naprium, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NAPROXEN


High impact information on NAPROXEN


Anatomical context of NAPROXEN

  • Each of three separate PG synthetase inhibitors introduced into the co-cultures-indomethacin 28 microM, 5, 8, 11, 14-eicosatetraynoic acid (ETYA) 33 microM, or Naprosyn 217 microM--decreased the suppression of the maternal T cells by a maximum of 65%, indicating the importance of PG for the suppression [10].
  • The effect of paracetamol against ulcerogenic agent, naprosyn on the gastric mucosa of albino rat was observed under dissecting as well as laboratory microscope [11].
  • To remove the retained pulpal components and residual NA, the pulp chamber of each disc was washed out with PBS and placed in an ultrasonic cleaner [12].
  • Under laboratory microscope, a significant increase in the mucosal thickness with the administration of paracetamol followed by naprosyn was observed, while the flattening of the surface epithelium with slight exfoliation may be attributed to relative increase of pepsin from the chief cell [11].
  • In the duodenum, there was a significant difference in favor of Naprelan over Naprosyn (P = 0.0236), and in favor of Naprelan over aspirin (P = 0.0086), but the difference between Naprosyn and aspirin was not significant (P = 0.6643) [13].

Associations of NAPROXEN with other chemical compounds


Gene context of NAPROXEN


Analytical, diagnostic and therapeutic context of NAPROXEN

  • After treatment, the mean headache frequency decreased to 4.1 per month (range, 0 to 12), a decrease of 62.4% (n = 54) [22].
  • Our results of the morphological and histochemical studies in rats support the clinical observations of mucosal destruction in stomach in patients after oral administration of Naprosyn [23].
  • We conclude the Naprosyn test remains a valuable diagnostic test to use to narrow differential diagnostic possibilities in patients with FUOs when a malignancy is a diagnostic consideration [24].


  1. Unilateral adrenal hemorrhage after chronic nonsteroidal anti-inflammatory drug use. Kraus, S.E., Siroky, M.B., Krane, R.J. Urology (1983) [Pubmed]
  2. Assessment of the efficacy of a nonsteroidal anti-inflammatory drug, Naprosyn, in the treatment of gingivitis. Johnson, R.H., Armitage, G.C., Francisco, C., Page, R.C. J. Periodont. Res. (1990) [Pubmed]
  3. Severe, primary dysmenorrhea treated with naproxen. A prospective, double-blind, crossover investigation. Hamann, G.O. Prostaglandins (1980) [Pubmed]
  4. Naproxen suppositories in postoperative pain and swelling after joint surgery. A comparative, double-blind study. Kvarnes, L. Scand. J. Rheumatol. (1984) [Pubmed]
  5. A comparison of Naprelan and Naprosyn in the treatment of osteoarthritis of the knee. Schiff, M.H. Am J. Orthop. (1996) [Pubmed]
  6. Synthesis and in vitro evaluation of novel morpholinyl- and methylpiperazinylacyloxyalkyl prodrugs of 2-(6-methoxy-2-naphthyl)propionic acid (Naproxen) for topical drug delivery. Rautio, J., Nevalainen, T., Taipale, H., Vepsäläinen, J., Gynther, J., Laine, K., Järvinen, T. J. Med. Chem. (2000) [Pubmed]
  7. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. Franssen, E.J., Jansen, R.W., Vaalburg, M., Meijer, D.K. Biochem. Pharmacol. (1993) [Pubmed]
  8. Naproxen (Naprosyn). Pharmacokinetics: therapeutical relevance and tolerance profile. Dahl, H. Cephalalgia : an international journal of headache. (1986) [Pubmed]
  9. A comparative study of Butacote and Naprosyn in ankylosing spondylitis. Ansell, B.M., Major, G., Liyanage, S.P., Gumpel, J.M., Seifert, M.H., Mathews, J.A., Engler, C. Ann. Rheum. Dis. (1978) [Pubmed]
  10. Strong prostaglandin associated suppression of the proliferation of human maternal lymphocytes by neonatal lymphocytes linked to T versus T cell interactions and differential PGE2 sensitivity. Papadogiannakis, N., Johnsen, S.A., Olding, L.B. Clin. Exp. Immunol. (1985) [Pubmed]
  11. The effect of paracetamol on naprosyn induced damage to gastric mucosa in albino rat. Janjua, M.Z., Draz, U. JPMA. The Journal of the Pakistan Medical Association. (1991) [Pubmed]
  12. Influence of the pulpal components on human dentine permeability in vitro. Puapichartdumrong, P., Ikeda, H., Suda, H. International endodontic journal. (2005) [Pubmed]
  13. Two comparative endoscopic evaluations of Naprelan. Hawkey, C., O'Morain, C., Murray, F., McCarthy, C., Tierney, D., Devane, J. Am J. Orthop. (1996) [Pubmed]
  14. A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. Calin, A., Elswood, J. J. Rheumatol. (1990) [Pubmed]
  15. Correlation between drug release kinetics from proteineous matrix and matrix structure: EPR and NMR study. Katzhendler, I., Mäder, K., Friedman, M. Journal of pharmaceutical sciences. (2000) [Pubmed]
  16. Diflunisal in rheumatoid arthritis. A controlled trial. Schorn, D. S. Afr. Med. J. (1981) [Pubmed]
  17. Isolated perfused rat kidney as a tool in the investigation of renal handling and effects of nonsteroidal antiinflammatory drugs. Cox, P.G., Moons, M.M., Slegers, J.F., Russel, F.G., van Ginneken, C.A. Journal of pharmacological methods. (1990) [Pubmed]
  18. Synthesis and cyclooxygenase inhibitory properties of novel (+) 2-(6-methoxy-2-naphthyl)propanoic acid (naproxene) derivatives. Abadi, A.H., Laufer, S., Lehmann, J. Arch. Pharm. (Weinheim) (2001) [Pubmed]
  19. Naproxen (Naprosyn) and the new non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Muirden, K.D. Med. J. Aust. (1978) [Pubmed]
  20. Facilitation of iontophoretic drug delivery through intact and caries-affected dentine. Puapichartdumrong, P., Ikeda, H., Suda, H. International endodontic journal. (2003) [Pubmed]
  21. Prediction of the efficacy of cutaneously applied nonsteroidal anti-inflammatory drugs from a lipophilic vehicle. Wenkers, B.P., Lippold, B.C. Arzneimittel-Forschung. (2000) [Pubmed]
  22. Prophylactic treatment of pediatric migraine. Lewis, D.W., Diamond, S., Scott, D., Jones, V. Headache. (2004) [Pubmed]
  23. Use of prostaglandin inhibitor, 2-(6-methoxy-2-naphthyl) propionic acid,with regard to morphological and enzymatic changes of gastric mucosa. Orlicz-Szczesna, G., Gabka, M. Zeitschrift für mikroskopisch-anatomische Forschung. (1990) [Pubmed]
  24. Fever of unknown origin (FUO) caused by multiple myeloma: The diagnostic value of the Naprosyn test. Cunha, B.A., Bouyarden, M., Hamid, N.S. Heart & lung : the journal of critical care. (2006) [Pubmed]
WikiGenes - Universities